Does Insurance Cover IV, Injection & Oral/Sublingual Ketamine?
By Michael Alvear, Health Author & Independent Researcher
My research is published on these scholarly platforms:
Last Updated:
Insurance Coverage of IV, Injection, and Oral Ketamine for Depression
Coverage and non-coverage patterns among 18 commercial insurers.
Understanding Coverage Status
The insurer has a written policy that explicitly covers that ketamine route for depression / treatment-resistant depression when specific criteria are met (often with prior authorization and strict rules).
The insurer has a written policy that explicitly classifies that ketamine route for depression as not covered (e.g., “not medically necessary,” “experimental,” or “investigational”).
The policy does not literally spell out “no” for this route, but the overall policy makes it effectively a no in real life. We use NO* in two situations:
- The insurer explicitly says IV ketamine for depression is not covered, and there is no separate policy that covers injection or oral ketamine for depression; or
- The insurer only covers IV ketamine inside a very narrow carve-out (for example, in-clinic IV Ketalar for TRD with strict criteria) and never mentions injection or oral ketamine at all.
In both cases, it is highly unlikely that a plan would secretly cover injection or oral ketamine for depression when it either refuses IV or barely covers IV under a tight program.
For patients: Treat NO* as “This route is almost certainly not covered; we just don’t have a sentence in the policy that says it in so many words.”
We could not find any clear public policy language about this route for depression from this insurer. In practice, that usually means:
- There is no established benefit the plan is promising for this treatment; and
- Claims are very likely to be denied unless a specific exception or custom arrangement is made.
Important: We keep “Not Stated” here only to be transparent that we don’t have an actual PDF line to quote, not because coverage is likely. If your insurer has “Not Stated” in this column, you should still assume it is not covered unless you get something different in writing from the plan.
Important Limits of This Table
- This table only looks at ketamine used to treat depression (usually treatment-resistant depression). It does not show coverage for anesthesia, pain management, or other uses.
- Spravato® (esketamine nasal spray) is handled under separate policies. Many insurers that refuse IV / injection / oral ketamine do cover Spravato® when criteria are met—that’s outside the scope of these columns.
- These entries summarize public insurer policy documents, not any one person’s specific plan. Coverage can vary by employer, state, network, and plan design, and policies change over time.
- Before starting treatment or assuming a bill will be covered, patients should confirm benefits directly with their insurer or have the clinic run a prior authorization / benefits check for their exact plan.
Data compiled from publicly available insurance policy documents. Coverage policies subject to change.
Always verify current coverage status directly with your insurance provider before pursuing treatment.
Ketamine Coverage by Insurance Company
Click your insurer to see coverage details
Does Kaiser Permanente Cover IV, Injection and Oral Ketamine?
The ketamine policy treats ketamine given by intranasal, intravenous, or subcutaneous routes as experimental for psychiatric conditions and lists depression as a non-covered diagnosis. It does not spell out any coverage criteria for oral or sublingual ketamine.
*Based on Kaiser Foundation Health Plan ketamine clinical review criteria published in the document “Ketamine for the Treatment of Depression and Other Psychiatric Disorders”.
NOT COVERED
IV ketamine infusions
The ketamine clinical review criteria state that ketamine given intranasally, intravenously, or subcutaneously is considered experimental and investigational for psychiatric diagnoses, and depression is specifically listed as a non-covered diagnosis. That language is what clinics run into when they try to bill IV ketamine for depression.
What this means for you:
If you want IV ketamine for depression while covered by Kaiser, you should expect to pay a clinic’s cash rate. This is why you usually do not see Kaiser listed as in-network for IV ketamine programs.
NOT COVERED
Injection ketamine (IM / subcutaneous)
Subcutaneous ketamine is grouped with intranasal and intravenous ketamine in the same experimental and investigational statement, with depression treated as a non-covered diagnosis. Although the policy language highlights subcutaneous administration, in practice IM (intramuscular) programs are treated the same way when used for depression.
What this means for you:
Clinics offering IM or subcutaneous ketamine for depression generally cannot bill Kaiser as a covered medical benefit, so they quote out-of-pocket prices similar to IV ketamine.
NOT STATED
Oral / sublingual ketamine
The ketamine clinical review criteria do not include any section on oral or sublingual ketamine for depression or other psychiatric diagnoses. There is no medical-necessity standard, no dosing guidance, and no indication that Kaiser intends to cover oral ketamine for depression.
What this means for you:
If a prescriber offers you oral or sublingual ketamine for depression while you are on a Kaiser plan, you should assume it will be an out-of-pocket treatment unless you receive a very clear, written confirmation of coverage from Kaiser.
Important fine print for Kaiser members
- This summary is based on Kaiser Foundation Health Plan non-Medicare clinical review criteria for ketamine for depression and other psychiatric disorders, as published in the ketamine criteria document “Ketamine for the Treatment of Depression and Other Psychiatric Disorders” and the related clinical review criteria resources.
- Kaiser notes that these clinical review criteria are tools used to administer plan benefits and do not offer medical advice or guarantee coverage; your actual contract and benefit documents control.
- Benefits can vary by employer group and specific product. To confirm your own situation, check your Evidence of Coverage or benefit booklet and call the Member Services number on your ID card.
Does HCSC (BCBS IL/TX/NM/OK/MT) Cover IV, Injection and Oral Ketamine?
The Blue Review article on ketamine infusion therapy describes intravenous ketamine infusions for psychiatric disorders as experimental, investigational and/or unproven, which is the language the plan uses for non-covered services. The newsletter references medical policy SUR702.016 for IV anesthetics, but public materials do not outline any coverage criteria for injection or oral ketamine for depression.
*Based on ketamine infusion information published for these Blue Cross and Blue Shield plans in the article “Blue Review – Fighting Fraud, Waste and Abuse: Ketamine Infusion Therapy (BCBSIL)”.
NOT COVERED
IV ketamine infusions
The clinical materials explain that intravenous ketamine infusions to treat psychiatric disorders are considered experimental, investigational and/or unproven, including cases involving chronic pain and other psychiatric conditions. In this language, “experimental and investigational” means the service is not treated as a covered benefit for depression.
What this means for you:
If you want IV ketamine for depression with this type of plan, you should expect clinics to bill you at their cash rate, and attempts to bill IV ketamine as a covered mental health service are likely to be denied.
NOT STATED
Injection ketamine (IM / subcutaneous)
None of the linked public materials provide specific criteria for intramuscular or subcutaneous ketamine for depression. When an insurer has already labeled IV ketamine infusions for psychiatric disorders as experimental, investigational and unproven, clinics generally assume that off-label injection routes are treated the same way.
What this means for you:
If a clinic offers IM or subcutaneous ketamine for depression, it will almost always be a self-pay service, and you should not expect your mental health benefits to reimburse those sessions.
NOT STATED
Oral / sublingual ketamine
The Blue Review article and related medical policy resources do not mention oral or sublingual ketamine for depression at all. When IV ketamine has already been placed in an experimental and non-covered category for psychiatric indications, it is highly unlikely that oral formulations would be handled more favorably.
What this means for you:
If you pursue oral or sublingual ketamine through a clinic, you should assume you will be paying the clinic’s cash rate and cannot rely on your plan to cover the medication or associated visits.
Important fine print for HCSC (BCBS IL/TX/NM/OK/MT) members
- This summary is based on ketamine infusion information from the Blue Review article “Blue Review – Fighting Fraud, Waste and Abuse: Ketamine Infusion Therapy (BCBSIL)”, the related Blue Review PDF newsletter, and the general medical policy index that references SUR702.016 for IV anesthetics.
- These materials describe how the plan evaluates ketamine services but do not guarantee payment for any specific member, diagnosis, clinic, or claim.
- Your actual benefits depend on your individual contract, so always review your Evidence of Coverage and call the Member Services number on your ID card before scheduling treatment.
- HCSC and its affiliated Blue Cross and Blue Shield plans operate in multiple states and product lines, and Medicare, Medicaid, or other products may have different ketamine rules than those summarized here.
Does UnitedHealthcare Cover IV, Injection and Oral Ketamine?
The commercial Ketalar/Spravato medical benefit drug policy classifies ketamine injection as investigational and not medically necessary for psychiatric disorders including depression. The coverage rationale treats ketamine injection for conditions such as depression, bipolar disorder, and posttraumatic stress disorder as not proven or medically necessary, and the policy does not spell out any coverage criteria for oral or sublingual ketamine for depression.
*Based on UnitedHealthcare commercial Ketalar/Spravato medical benefit drug policy published in the document “Commercial – national Ketalar/Spravato medical benefit drug policy”.
NOT COVERED
IV ketamine infusions
The coverage rationale for ketamine injection states that the drug is investigational and therefore not proven or medically necessary for psychiatric disorders, including depression, bipolar disorder, and posttraumatic stress disorder. When a service is labeled investigational and not medically necessary in this way, it is not treated as a covered benefit for depression.
What this means for you:
If you pursue IV ketamine infusions for depression, you should expect clinics to treat them as a self-pay service, and claims billed to your plan are likely to be denied.
NOT COVERED
Injection ketamine (IM / subcutaneous)
The Ketalar/Spravato policy explains that the ketamine injection criteria apply whether the drug is given by IV or IM routes for psychiatric indications. Because ketamine injection is classified as investigational and not medically necessary for psychiatric disorders including depression, clinics treat IM or subcutaneous ketamine for depression as non-covered as well.
What this means for you:
If a clinic offers IM or subcutaneous ketamine for depression, it will almost always be a cash-pay service rather than something your plan reimburses as a mental health benefit.
NOT STATED
Oral / sublingual ketamine
The commercial Ketalar/Spravato policy does not discuss oral or sublingual ketamine for depression and focuses only on ketamine injection and Spravato nasal spray. When an insurer already denies ketamine injection for psychiatric disorders as investigational and not medically necessary, it is highly unlikely to cover off-label oral ketamine for depression.
What this means for you:
If you work with a clinic that prescribes oral or sublingual ketamine, you should assume you will be paying the clinic’s cash rate and cannot rely on your plan to cover the medication or associated visits.
Important fine print for UnitedHealthcare members
- This summary is based on the UnitedHealthcare commercial Ketalar/Spravato medical benefit drug policy and related materials, including the policy document “Commercial – national Ketalar/Spravato medical benefit drug policy”, the commercial medical and drug policy index, and the commercial medical policy update bulletin.
- These materials describe how the plan evaluates ketamine services but do not guarantee payment for any specific member, diagnosis, clinic, or claim.
- Your actual benefits depend on your individual contract, so always review your Evidence of Coverage and call the Member Services number on your ID card before scheduling treatment.
- UnitedHealthcare administers multiple product lines, and employer plans, Medicare, Medicaid, or other products may have different ketamine rules than those summarized here.
Anthem Blue Cross Blue Shield: IV, Injection, and Oral Ketamine Coverage for Depression
The CarelonRx ketamine injection clinical criteria limit approval of Ketalar to anesthesia and certain acute pain indications. For all other indications, including major depressive disorder and other psychiatric conditions, ketamine injection is described as a drug that may not be approved, and the document does not outline any coverage criteria for oral or sublingual ketamine for depression.
*Based on CarelonRx ketamine injection clinical criteria used for Anthem commercial plans, as published in the document “Clinical Criteria – Ketalar (ketamine injection)”.
NOT COVERED
IV ketamine infusions
The CarelonRx criteria restrict Ketalar approval to anesthesia and selected acute pain situations. They state that ketamine injection may not be approved when criteria for anesthesia or acute pain are not met and for all other indications, including major depressive disorder and other psychiatric disorders. Clinics interpret this as a clear non-coverage stance for IV ketamine for depression.
What this means for you:
If you seek IV ketamine infusions for depression, you should expect clinics to treat them as a self-pay service, and claims billed to your plan are likely to be denied.
NOT COVERED
Injection ketamine (IM / subcutaneous)
The same CarelonRx clinical criteria apply to Ketalar whether it is administered by IV or IM routes for psychiatric indications. Because major depressive disorder and related conditions appear on the list of indications that may not be approved, injection ketamine for depression is treated as not medically necessary and not approvable under these criteria.
What this means for you:
If a clinic offers IM or subcutaneous ketamine for depression, it will almost always be a cash-pay service, and you should not expect your plan to reimburse those treatments as a mental health benefit.
NOT STATED
Oral / sublingual ketamine
The CarelonRx document is written specifically for Ketalar (ketamine injection) and does not discuss any oral or sublingual ketamine products for depression. When an insurer already refuses ketamine injection for psychiatric indications, it is highly unlikely to treat off-label oral ketamine more favorably.
What this means for you:
If you work with a clinic that prescribes oral or sublingual ketamine, you should assume you will be paying the clinic’s cash rate and cannot rely on your plan to cover the medication or associated visits.
Important fine print for Anthem Blue Cross Blue Shield members
- This summary is based on CarelonRx ketamine injection clinical criteria used for Anthem commercial plans, including the document “Clinical Criteria – Ketalar (ketamine injection)”, the CarelonRx clinical criteria index, and the Anthem pharmacy clinical criteria page.
- These criteria describe how ketamine injection requests are evaluated but do not guarantee payment for any specific member, diagnosis, clinic, or claim.
- Your actual benefits depend on your individual contract, so always review your Evidence of Coverage and call the Member Services number on your ID card before scheduling treatment.
- Anthem operates in multiple states and product lines, and employer plans, Medicare, Medicaid, or other products may have different ketamine rules than those summarized here.
Does Aetna Cover IV, Injection and Oral Ketamine?
The clinical policy bulletin on ketamine for depression explains that Aetna considers ketamine given intramuscularly, intranasally, intravenously, orally, or subcutaneously experimental, investigational, or unproven for depression. In this policy language, a service labeled experimental or unproven is not treated as a covered benefit for depressive disorders.
*Based on Aetna clinical policy bulletin “Ketamine for the Treatment of Depression and Other Selected Indications (CPB 0938)”.
NOT COVERED
IV ketamine infusions
The ketamine bulletin explains that Aetna considers ketamine given intravenously, along with other routes, experimental, investigational, or unproven for depression. When a service is placed in this category, there is no standard path for it to be treated as a covered benefit for depressive disorders.
What this means for you:
If you pursue IV ketamine infusions for depression, you should expect clinics to treat them as a self-pay service, and claims sent to your plan are likely to be denied as experimental or investigational.
NOT COVERED
Injection ketamine (IM / subcutaneous)
The same policy language that applies to IV ketamine also applies to intramuscular and subcutaneous routes, because the bulletin groups these routes together. By labeling ketamine injection experimental, investigational, or unproven for depression, the policy signals that these treatments are not medically necessary under the plan’s standards.
What this means for you:
If a clinic offers IM or subcutaneous ketamine for depression, it will almost always be a cash-pay service, and you should not expect your plan to reimburse those injections as a mental health benefit.
NOT COVERED
Oral / sublingual ketamine
The bulletin explicitly includes oral ketamine in the list of routes Aetna considers experimental, investigational, or unproven for depression. When a route is described this way, there is no published route to having it approved as a covered benefit for depressive disorders.
What this means for you:
If you work with a clinic that prescribes oral or sublingual ketamine for depression, you should assume you will be paying the clinic’s cash rate and cannot rely on your plan to cover the medication or related visits.
Important fine print for Aetna members
- This summary is based on Aetna clinical policy bulletins including “Ketamine for the Treatment of Depression and Other Selected Indications (CPB 0938)”, the related bulletin CPB 0950, and the general Aetna medical clinical policy bulletin index.
- These bulletins describe how Aetna evaluates ketamine services but do not guarantee payment for any specific member, diagnosis, clinic, or claim.
- Your actual benefits depend on your individual contract, so always review your Evidence of Coverage and call the Member Services number on your ID card before scheduling treatment.
- Aetna offers multiple product lines, and employer plans, Medicare, Medicaid, or other products may have different ketamine rules than those summarized here.
Does Florida Blue Cover IV, Injection and Oral Ketamine?
The Spravato nasal spray medical coverage guideline is the only Florida Blue policy that addresses a ketamine-based treatment for depression, and it focuses solely on intranasal esketamine. The guideline notes that Spravato is for nasal use only and that the patient is not receiving concomitant ketamine therapy, without outlining any coverage position for IV, intramuscular, subcutaneous, oral, or sublingual ketamine.
*Based on Florida Blue Spravato nasal spray coverage materials, including the medical coverage guideline “Spravato (esketamine) Nasal Spray – Medical Coverage Guideline (PH-0481/09-J3000-37)”.
NOT STATED
IV ketamine infusions
The Spravato coverage guideline is written around intranasal esketamine as the defined ketamine-based option for treatment-resistant depression. It specifies that Spravato is for nasal use only and that the patient is not receiving concomitant ketamine therapy, but it does not describe any circumstances where IV ketamine infusions for depression would be considered a covered benefit.
What this means for you:
If you pursue IV ketamine infusions for depression, clinics will almost always treat them as self-pay, and attempts to bill them as a covered mental health service are very likely to be denied.
NOT STATED
Injection ketamine (IM / subcutaneous)
The same Spravato guideline does not create any separate criteria for intramuscular or subcutaneous ketamine, even though it clearly defines nasal Spravato dosing and monitoring requirements. By limiting ketamine-based coverage to intranasal esketamine and prohibiting concomitant ketamine therapy, the policy leaves no defined path for IM or subcutaneous ketamine to be approved for depression.
What this means for you:
If a clinic offers IM or subcutaneous ketamine for depression, you should assume those sessions will be cash-pay and not reimbursed through your standard mental health benefits.
NOT STATED
Oral / sublingual ketamine
The Spravato medical coverage guideline repeatedly emphasizes that the product is for nasal use only and does not reference any oral or sublingual ketamine products for depression. When the only defined ketamine-based benefit is Spravato nasal spray, there is no indication that off-label oral ketamine would be handled as a covered service.
What this means for you:
If you work with a clinic that prescribes oral or sublingual ketamine, you should expect to pay the clinic’s cash rate and not rely on your plan to cover the medication or associated visits.
Important fine print for Florida Blue members
- This summary is based on Florida Blue Spravato nasal spray materials, including the medical coverage guideline “Spravato (esketamine) Nasal Spray – Medical Coverage Guideline (PH-0481/09-J3000-37)”, the policy page Spravato (esketamine) Nasal Spray – Medical Policies, and the broader medical policies and coverage guidelines index.
- These documents describe how Spravato requests are evaluated but do not guarantee payment for any specific member, diagnosis, clinic, or claim.
- Your actual benefits depend on your individual contract, so always review your Evidence of Coverage and call the Member Services number on your ID card before scheduling treatment.
- Florida Blue and related plans may have different rules across product lines, and separate policies for Spravato, IV ketamine, or other treatments may apply to Medicare, Medicaid, or employer-specific benefits.
Does Cigna Healthcare Cover IV, Injection and Oral Ketamine?
The outpatient Ketalar coverage criteria state that ketamine intravenous use for any outpatient indication, including major depressive disorder, is considered not medically necessary. Publicly available materials do not describe coverage criteria for other ketamine injection routes or for oral or sublingual ketamine for depression, so these routes function like cash-pay options in practice.
*Based on Cigna Healthcare pharmacy coverage materials for Ketalar, including the document “Unassigned Drug Code Outpatient Medical Precertification – Ketalar (ketamine intravenous)”.
NOT COVERED
IV ketamine infusions
The Ketalar outpatient coverage position explains that ketamine intravenous use for any outpatient indication is considered not medically necessary, and it specifically includes major depressive disorder in that determination. When a service is labeled not medically necessary in this way, there is no standard path for it to be treated as a covered benefit for depression.
What this means for you:
If you pursue IV ketamine infusions for depression, clinics will almost always treat them as self-pay, and claims sent to your plan are very likely to be denied as not medically necessary.
NOT STATED
Injection ketamine (IM / subcutaneous)
The available coverage materials focus on Ketalar given intravenously and do not create a separate coverage pathway for intramuscular or subcutaneous ketamine for depression. When the same product is already considered not medically necessary for outpatient IV use in major depressive disorder, clinics generally assume that off-label IM or subcutaneous use for depression will be treated the same way.
What this means for you:
If a clinic offers IM or subcutaneous ketamine for depression, you should expect those sessions to be cash-pay and not reimbursed as a covered mental health benefit.
NOT STATED
Oral / sublingual ketamine
The Ketalar outpatient policy does not discuss oral or sublingual ketamine for depression, and other publicly available materials focus on compounded medications in general or on esketamine nasal spray rather than oral ketamine. In this context, there is no published route for oral or sublingual ketamine to be treated as a covered benefit for depression.
What this means for you:
If you work with a clinic that prescribes oral or sublingual ketamine, you should assume you will be paying the clinic’s cash rate and not using your standard mental health benefits for the medication or associated visits.
Important fine print for Cigna Healthcare members
- This summary is based on Cigna Healthcare pharmacy coverage policies, including the Ketalar coverage position in “Unassigned Drug Code Outpatient Medical Precertification – Ketalar (ketamine intravenous)”, the coverage criteria for compounded medications, and the esketamine nasal spray coverage criteria.
- These documents describe how requests for Ketalar and related therapies are evaluated but do not guarantee payment for any specific member, diagnosis, clinic, or claim.
- Your actual benefits depend on your individual contract, so always review your Evidence of Coverage and call the Member Services number on your ID card before scheduling treatment.
- Cigna Healthcare offers multiple product lines, and employer plans, Medicare, Medicaid, or other products may have different ketamine rules than those summarized here.
Does Ambetter Cover IV, Injection and Oral Ketamine?
The Ketalar clinical policy for Ambetter lays out criteria for intravenous ketamine in treatment-resistant depression and major depressive disorder, requiring IV administration plus multiple failed antidepressant treatments. The same documents do not create any explicit coverage pathway for intramuscular, subcutaneous, oral, or sublingual ketamine for depression, so those routes are left undefined.
*Based on Ambetter clinical policy “Clinical Policy: Ketamine (Ketalar) – CP.PMN.296”.
COVERED WITH PRIOR AUTH
IV ketamine infusions
The Ketalar policy explains that intravenous ketamine can be approved for treatment-resistant depression and major depressive disorder only when specific conditions are satisfied. These include that the request is for IV ketamine and that you have already failed at least two antidepressants plus one augmentation therapy. This is a narrow pathway aimed at people whose depression has not responded to standard medication strategies.
What this means for you:
If you are seeking IV ketamine for depression, a clinic that works with Ambetter may be able to obtain prior authorization when you clearly meet the treatment-resistant criteria, but coverage is not automatic and not all clinics participate with these plans.
NOT STATED
Injection ketamine (IM / subcutaneous)
The same policy that defines IV ketamine approval never carves out a separate role for intramuscular or subcutaneous ketamine in depression. Because the criteria are written specifically around intravenous administration for treatment-resistant depression, clinics generally assume that off-label IM or subcutaneous protocols for depression will not be approved under this policy.
What this means for you:
If a clinic offers IM or subcutaneous ketamine for depression, you should expect those sessions to be treated as cash-pay unless the clinic can show you very specific evidence that a prior authorization for your case has been granted.
NOT STATED
Oral / sublingual ketamine
The Ketalar clinical policy does not mention oral or sublingual ketamine products anywhere in its depression criteria. When only IV ketamine is defined for treatment-resistant depression and major depressive disorder, there is no indication that off-label oral ketamine would be handled as a covered mental health benefit.
What this means for you:
If you work with a clinic that prescribes oral or sublingual ketamine, you should assume you will be paying the clinic’s cash rate and cannot rely on your Ambetter plan to cover the medication or associated visits.
Important fine print for Ambetter members
- This summary is based on Ambetter and Centene pharmacy policies, including “Clinical Policy: Ketamine (Ketalar) – CP.PMN.296”, the related ketamine policy at CP.PMN.199, and other materials in the Ambetter pharmacy policy library.
- These criteria describe how requests for ketamine are evaluated but do not guarantee payment for any specific member, diagnosis, clinic, or claim.
- Your actual benefits depend on your individual contract, so always review your Evidence of Coverage and call the Member Services number on your ID card before scheduling treatment.
- Centene and Ambetter offer multiple products in different states, and Medicaid, marketplace, employer, or other plan designs may have ketamine rules that differ from what is summarized here.
Does Highmark Blue Cross Blue Shield Cover IV, Injection and Oral Ketamine?
The Highmark intravenous anesthetics policy allows ketamine (Ketalar) to be considered medically necessary for treatment-resistant or major depressive disorder only when all policy criteria are met and states that ketamine not meeting those criteria is considered not medically necessary. The policy focuses on IV infusion and does not create separate coverage determinations for intramuscular, subcutaneous, oral, or sublingual ketamine for depression.
*Based on Highmark commercial medical policy “Intravenous Anesthetics for Off-Label Indications (I-32-012)”, including the TRD/MDD section on ketamine (Ketalar).
COVERED WITH PRIOR AUTH
IV ketamine infusions
The policy explains that ketamine (Ketalar) may be considered medically necessary for adults with treatment-resistant or major depressive disorder when all listed criteria are satisfied and explicitly states that ketamine not meeting those criteria is considered not medically necessary. The approval pathway is narrow and tied to a specific TRD/MDD section rather than to general off-label use.
What this means for you:
If you are pursuing IV ketamine infusions for depression, a clinic that works with Highmark may be able to obtain prior authorization when you clearly meet the TRD/MDD criteria, but coverage is not automatic and any request that does not match the policy is likely to be denied.
NOT STATED
Injection ketamine (IM / subcutaneous)
The same policy is framed around IV anesthetics and addresses Ketalar under an IV infusion code, without carving out a separate role for intramuscular or subcutaneous ketamine in depression. When coverage criteria are written specifically for IV ketamine and no language supports IM ketamine for depressive disorders, clinics typically treat IM protocols as non-covered.
What this means for you:
If a clinic offers IM or subcutaneous ketamine for depression, you should expect those sessions to be cash-pay unless the clinic can show you a prior authorization approval for your specific case.
NOT STATED
Oral / sublingual ketamine
The intravenous anesthetics policy does not mention oral or sublingual ketamine for depression and focuses instead on IV agents used off-label for psychiatric indications. Without any policy language supporting oral ketamine for depressive disorders, there is no standard path for these formulations to be approved as covered benefits.
What this means for you:
If you work with a clinic that prescribes oral or sublingual ketamine, you should assume you will be paying the clinic’s cash rate and not relying on your Highmark plan to cover the medication or associated visits.
Important fine print for Highmark Blue Cross Blue Shield members
- This summary is based on Highmark commercial medical policy “Intravenous Anesthetics for Off-Label Indications (I-32-012)”, including the section that addresses ketamine (Ketalar) for treatment-resistant and major depressive disorder.
- The policy describes how requests for IV ketamine are evaluated but does not guarantee payment for any particular member, diagnosis, clinic, or claim.
- Your actual benefits depend on your individual contract, so always review your Evidence of Coverage and call the Member Services number on your ID card before scheduling treatment.
- Highmark and affiliated Blue Cross Blue Shield plans may have different rules across states and product lines, and Medicare, Medicaid, or employer-specific plans can use different criteria than those summarized here.
Does Blue Cross NC Cover IV, Injection and Oral Ketamine?
The commercial medical policy on intravenous anesthetics states that IV anesthetics, including ketamine, for chronic pain and psychiatric disorders (including treatment-resistant depression) are considered investigational and not covered. The policy focuses on IV infusions and does not create any explicit coverage pathway for intramuscular, oral, or sublingual ketamine for depression.
*Based on the Blue Cross NC commercial medical policy “Intravenous Anesthetics for the Treatment of Chronic Pain and Psychiatric Disorders”.
NOT COVERED
IV ketamine infusions
The medical policy classifies IV anesthetics, including ketamine, as investigational when used for chronic pain and psychiatric disorders such as treatment-resistant depression. It further explains that services considered investigational are not covered benefits, which puts IV ketamine for depression in the non-covered category.
What this means for you:
If you pursue IV ketamine infusions for depression, clinics will almost always treat them as self-pay, and claims sent to your plan are very likely to be denied as investigational and not covered.
NOT STATED
Injection ketamine (IM / subcutaneous)
The same policy is written around IV anesthetics and does not provide any separate determination for intramuscular or subcutaneous ketamine in depression. When IV ketamine is already considered investigational and non-covered for psychiatric indications, clinics generally assume that off-label IM or subcutaneous protocols for depression will be treated the same way.
What this means for you:
If a clinic offers IM or subcutaneous ketamine for depression, you should expect those sessions to be cash-pay and not reimbursed as a standard mental health benefit.
NOT STATED
Oral / sublingual ketamine
The intravenous anesthetics policy touches on oral ketamine only in background discussion and does not set coverage criteria for oral or sublingual ketamine in depression. Without any supportive policy language, there is no published path for these formulations to be treated as covered benefits for depressive disorders.
What this means for you:
If you work with a clinic that prescribes oral or sublingual ketamine, you should assume you will be paying the clinic’s cash rate and not relying on your Blue Cross NC plan to cover the medication or associated visits.
Important fine print for Blue Cross NC members
- This summary is based on the Blue Cross NC commercial medical policy “Intravenous Anesthetics for the Treatment of Chronic Pain and Psychiatric Disorders”, including sections that address ketamine as an IV anesthetic.
- The policy describes how requests for IV anesthetics such as ketamine are evaluated but does not guarantee payment for any specific member, diagnosis, clinic, or claim.
- Your actual benefits depend on your individual contract, so always review your Evidence of Coverage and call the Member Services number on your ID card before scheduling treatment.
- Blue Cross NC and related plans may have different rules across products and funding arrangements, and separate criteria can apply to Medicare, Medicaid, or employer-specific plans.
Does Blue Cross Blue Shield of Massachusetts Cover IV, Injection and Oral Ketamine?
The medical policy on esketamine nasal spray and intravenous ketamine explains that IV ketamine can be covered for treatment-resistant depression and certain mental health conditions when specific medical necessity criteria are met. The same materials focus on IV infusions and intranasal esketamine and do not create any explicit coverage pathway for intramuscular, oral, or sublingual ketamine for depression.
*Based on Blue Cross Blue Shield of Massachusetts medical policy “Esketamine Nasal Spray (Spravato) and Intravenous Ketamine for Mental Health Conditions (Medical Policy 087)”.
COVERED WITH PRIOR AUTH
IV ketamine infusions
The medical policy explains that intravenous ketamine shares the same medical necessity criteria as intranasal esketamine for treatment-resistant depression and related mental health conditions. Coverage requires that all policy 087 criteria are satisfied, and ketamine that does not meet those criteria is considered not medically necessary.
What this means for you:
If you are seeking IV ketamine infusions for depression, a participating clinic may be able to obtain prior authorization when you clearly meet the treatment-resistant criteria, but coverage is not automatic and requests that fall outside the policy are likely to be denied.
NOT STATED
Injection ketamine (IM / subcutaneous)
The same policy and related billing guidance focus on IV ketamine infusions and intranasal esketamine, without carving out a separate role for intramuscular ketamine in depression. When coverage criteria are written only for IV ketamine, clinics generally assume that off-label IM or subcutaneous protocols for depression will not be approved.
What this means for you:
If a clinic offers IM or subcutaneous ketamine for depression, you should expect those sessions to be cash-pay unless the clinic can show you a specific prior authorization approval for your case.
NOT STATED
Oral / sublingual ketamine
The medical policy on esketamine nasal spray and IV ketamine does not mention oral or sublingual ketamine products for depression or provide medical necessity criteria for them. Without any supportive policy language, there is no standard path for oral ketamine to be treated as a covered benefit for depressive disorders.
What this means for you:
If you work with a clinic that prescribes oral or sublingual ketamine, you should assume you will be paying the clinic’s cash rate and not relying on your Blue Cross Blue Shield of Massachusetts coverage for the medication or associated visits.
Important fine print for Blue Cross Blue Shield of Massachusetts members
- This summary is based on Blue Cross Blue Shield of Massachusetts materials including medical policy “Esketamine Nasal Spray (Spravato) and Intravenous Ketamine for Mental Health Conditions (Medical Policy 087)” and the related prior authorization request form.
- These documents describe how esketamine and IV ketamine requests are evaluated but do not guarantee payment for any specific member, diagnosis, clinic, or claim.
- Your actual benefits depend on your individual contract, so always review your Evidence of Coverage and call the Member Services number on your ID card before scheduling treatment.
- Blue Cross Blue Shield of Massachusetts offers multiple products, and employer plans or other arrangements may have ketamine rules that differ from what is summarized here.
Does Blue Cross Blue Shield of Michigan Cover IV, Injection and Oral Ketamine?
The medical policy on intravenous anesthetics explains that IV anesthetic infusions such as ketamine for psychiatric disorders, including treatment-resistant depression, are considered investigational and not covered. The policy is written around IV administration and does not create explicit coverage criteria for intramuscular, oral, or sublingual ketamine for depression.
*Based on Blue Cross Blue Shield of Michigan medical policy “Intravenous Anesthetics for the Treatment of Chronic Pain and Psychiatric Disorders”.
NOT COVERED
IV ketamine infusions
The medical policy explains that intravenous infusion of anesthetics such as ketamine for psychiatric disorders, including but not limited to treatment-resistant depression, is considered investigational. Services labeled investigational in this way are not treated as covered benefits, which places IV ketamine for depression in the non-covered category.
What this means for you:
If you pursue IV ketamine infusions for depression, clinics will almost always treat them as self-pay, and claims sent to your plan are very likely to be denied as investigational and not covered.
NOT STATED
Injection ketamine (IM / subcutaneous)
The same policy is framed around IV anesthetic infusions and does not provide a separate coverage determination for intramuscular or subcutaneous ketamine in depression. When IV ketamine is already considered investigational and non-covered for psychiatric indications, clinics generally assume that off-label IM or subcutaneous protocols for depression will be treated the same way.
What this means for you:
If a clinic offers IM or subcutaneous ketamine for depression, you should expect those sessions to be cash-pay and not reimbursed as a standard mental health benefit.
NOT STATED
Oral / sublingual ketamine
The intravenous anesthetics policy mentions oral ketamine only in background discussion, noting that test infusions have been used to assess whether medications such as oral ketamine may be effective. It does not set medical necessity criteria or a coverage decision for oral or sublingual ketamine in depression.
What this means for you:
If you work with a clinic that prescribes oral or sublingual ketamine, you should assume you will be paying the clinic’s cash rate and not relying on your Blue Cross Blue Shield of Michigan coverage for the medication or associated visits.
Important fine print for Blue Cross Blue Shield of Michigan members
- This summary is based on Blue Cross Blue Shield of Michigan materials including the medical policy “Intravenous Anesthetics for the Treatment of Chronic Pain and Psychiatric Disorders”, related policy documents such as additional anesthetic policy guidance, and provider communications in the ereferrals news and updates.
- These materials describe how requests for IV anesthetics such as ketamine are evaluated but do not guarantee payment for any specific member, diagnosis, clinic, or claim.
- Your actual benefits depend on your individual contract, so always review your Evidence of Coverage and call the Member Services number on your ID card before scheduling treatment.
- Blue Cross Blue Shield of Michigan offers multiple products, and employer plans or other arrangements may have ketamine rules that differ from what is summarized here.
Does Horizon Blue Cross Blue Shield of New Jersey Cover IV, Injection and Oral Ketamine?
The medical policy on intravenous anesthetics classifies IV ketamine infusions for psychiatric disorders, including depression, as investigational and therefore not covered. The policy is limited to IV anesthetic infusions and mentions oral ketamine only in background discussion, without creating any coverage pathway for intramuscular, oral, or sublingual ketamine for depression.
*Based on Horizon Blue Cross Blue Shield of New Jersey medical policy “Intravenous Anesthetics for the Management of Chronic Pain and Depression (Policy 035)”.
NOT COVERED
IV ketamine infusions
The policy’s coverage statement explains that intravenous infusion of anesthetics, including ketamine, for chronic pain and psychiatric disorders such as depression is considered investigational. It also clarifies that the plan does not provide coverage for investigational services, which places IV ketamine for depression firmly outside covered mental health benefits.
What this means for you:
If you pursue IV ketamine infusions for depression, clinics will almost always treat them as self-pay, and any claims sent to your plan are very likely to be denied as investigational and not covered.
NOT STATED
Injection ketamine (IM / subcutaneous)
The same policy is framed around intravenous anesthetic infusions and does not specifically discuss intramuscular or subcutaneous ketamine for psychiatric indications. When IV ketamine is already considered investigational and non-covered for depression, clinics generally assume that off-label IM or subcutaneous protocols will be treated the same way.
What this means for you:
If a clinic offers IM or subcutaneous ketamine for depression, you should expect those sessions to be cash-pay and not reimbursed as a standard mental health benefit.
NOT STATED
Oral / sublingual ketamine
In the background discussion, the policy notes that IV test infusions have been used in treatment planning to assess whether oral ketamine may be effective, but it stops short of setting coverage criteria or a medical necessity statement for oral or sublingual ketamine. Without explicit coverage language, there is no standard path for these formulations to be treated as covered benefits for depression.
What this means for you:
If you work with a clinic that prescribes oral or sublingual ketamine, you should assume you will be paying the clinic’s cash rate and not relying on your Horizon Blue Cross Blue Shield of New Jersey coverage for the medication or associated visits.
Important fine print for Horizon Blue Cross Blue Shield of New Jersey members
- This summary is based on Horizon policies and communications including the medical policy “Intravenous Anesthetics for the Management of Chronic Pain and Depression (Policy 035)”, the online medical policy section view, and the provider news article “Medical policy revision: intravenous anesthetics for the management of chronic pain and depression”.
- These materials describe how IV anesthetic infusions such as ketamine are evaluated but do not guarantee payment for any specific member, diagnosis, clinic, or claim.
- Your actual benefits depend on your individual contract, so always review your Evidence of Coverage and call the Member Services number on your ID card before scheduling treatment.
- Horizon Blue Cross Blue Shield of New Jersey offers multiple products, and employer plans, Medicaid, Medicare, or other arrangements may have ketamine rules that differ from what is summarized here.
Does Independence Blue Cross Cover IV, Injection and Oral Ketamine?
The intravenous ketamine and intranasal esketamine policy classifies IV ketamine for depression as experimental and investigational and therefore not covered outside anesthesia or cancer pain indications. The document focuses on IV Ketalar and Spravato and does not describe any coverage path for intramuscular, oral, or sublingual ketamine for depression.
*Based on Independence Blue Cross medical policy “Intravenous Ketamine (Ketalar®) and Intranasal Esketamine (Spravato®) (Policy 08.01.80c)”.
NOT COVERED
IV ketamine infusions
The ketamine policy explains that ketamine (Ketalar) for the treatment of depression is considered experimental and investigational and therefore not covered, while allowing limited use in anesthesia or cancer pain. When a service is classified as experimental or investigational in this way, it is not treated as a covered mental health benefit.
What this means for you:
If you pursue IV ketamine infusions for depression, clinics will almost always treat them as self-pay, and claims sent to your plan are very likely to be denied as experimental and not covered.
NOT STATED
Injection ketamine (IM / subcutaneous)
The same policy lays out criteria only for intravenous ketamine and does not create a separate role for intramuscular or subcutaneous ketamine in depression. When IV ketamine for depression is already labeled experimental and not covered, clinics generally assume that off-label IM protocols will be handled the same way.
What this means for you:
If a clinic offers IM or subcutaneous ketamine for depression, you should expect those sessions to be cash-pay and not reimbursed as a standard mental health benefit.
NOT STATED
Oral / sublingual ketamine
The IV ketamine and intranasal esketamine policy does not mention oral or sublingual ketamine for depression or provide medical necessity criteria for these routes. Without explicit coverage language, there is no standard path for oral ketamine to be treated as a covered benefit for depressive disorders.
What this means for you:
If you work with a clinic that prescribes oral or sublingual ketamine, you should assume you will be paying the clinic’s cash rate and not relying on your Independence Blue Cross coverage for the medication or associated visits.
Important fine print for Independence Blue Cross members
- This summary is based on Independence Blue Cross and related plan materials, including medical policy “Intravenous Ketamine (Ketalar®) and Intranasal Esketamine (Spravato®) (Policy 08.01.80c)” and the corresponding AmeriHealth commercial policy page.
- These documents describe how IV ketamine and Spravato requests are evaluated but do not guarantee payment for any specific member, diagnosis, clinic, or claim.
- Your actual benefits depend on your individual contract, so always review your Evidence of Coverage and call the Member Services number on your ID card before scheduling treatment.
- Independence Health Group and its affiliated plans may have different rules across products and funding arrangements, and employer, Medicaid, or Medicare plans can apply different ketamine criteria than those summarized here.
Does Humana Cover IV, Injection and Oral Ketamine?
The available Humana commercial policy portal does not publish a clear position on IV or other forms of ketamine for depression. In a related Humana Military TRICARE Spravato policy, ketamine administered in any form is explicitly described as not covered for the treatment of depression, which is a strong signal that clinics should not expect routine coverage for IV, injection, oral, or sublingual ketamine through Humana.
*Based on Humana Military TRICARE Spravato coverage materials, including the document “Spravato (esketamine) nasal spray – TRICARE policy MP22-026E”.
NOT STATED
IV ketamine infusions
The TRICARE Spravato policy explains that ketamine, administered in any form, is not covered for the treatment of depression, which includes IV infusions as one of the excluded routes. Humana’s commercial policy portal does not publish its own IV ketamine criteria for depression, so clinics typically read the combination of silence on commercial coverage and explicit TRICARE exclusion as a strong non-coverage signal.
What this means for you:
If you pursue IV ketamine for depression with a Humana-affiliated plan, you should expect clinics to bill you at their cash rate and treat IV infusions as self-pay, unless a clinic can show you a very specific written authorization for your case.
NOT STATED
Injection ketamine (IM / subcutaneous)
Humana’s public policy sources do not lay out medical necessity criteria for intramuscular or subcutaneous ketamine in depression. When a related TRICARE policy has already stated that ketamine in any form is not covered for depression, and commercial materials offer no IM carve-out, clinics assume that IM ketamine for depression will not be paid as a covered behavioral health benefit.
What this means for you:
If a clinic offers IM or subcutaneous ketamine for depression, you should plan on paying the clinic’s cash rate and not count on reimbursement from your Humana coverage.
NOT STATED
Oral / sublingual ketamine
The Humana commercial policy portal and the TRICARE Spravato document do not publish coverage criteria for oral or sublingual ketamine in depression. With no supportive language and a clear TRICARE statement that ketamine in any form is not covered for depression, oral formulations are treated as off-label, self-pay options rather than covered mental health treatments.
What this means for you:
If you work with a clinic that prescribes oral or sublingual ketamine, you should assume you will be paying out of pocket for both the medication and related visits, unless you have explicit written confirmation of coverage for your specific situation.
Important fine print for Humana members
- This summary is based on Humana policy sources including the Humana Medical and Pharmacy Coverage Policies portal, the Humana Military TRICARE Spravato policy MP22-026E, and the Spravato continued request form at Humana provider resources.
- These materials describe how ketamine and Spravato requests are evaluated in TRICARE and hint at Humana’s broader approach, but they do not guarantee payment for any specific member, diagnosis, clinic, or claim.
- Your actual benefits depend on your individual contract, so always review your Evidence of Coverage and call the Member Services number on your ID card before scheduling treatment.
- Humana offers multiple products, including commercial, military, and other lines of business, and ketamine rules can differ across these products even when they are administered by the same company.
Does Molina Healthcare Cover IV, Injection and Oral Ketamine?
The Spravato esketamine nasal spray clinical criteria document lists intravenous ketamine infusions as not FDA approved and not a covered benefit, treating IV ketamine for depression as an experimental or investigational use. The same materials do not create any coverage pathway for intramuscular, oral, or sublingual ketamine for depression, so those routes are effectively treated as non-covered as well.
*Based on Molina clinical criteria for Spravato esketamine nasal spray, including the document “Spravato esketamine nasal spray clinical criteria IME-PAM-021” and related Iowa Medicaid materials such as the coverage criteria posted by the state at Iowa HHS pharmacy and medical policy resources.
NOT COVERED
IV ketamine infusions
The Spravato clinical criteria explicitly list use of ketamine as an intravenous infusion as not FDA approved and not a covered benefit, placing IV ketamine for depression under the experimental or investigational category. When a service is labeled this way, it is not treated as a medically necessary covered treatment for depressive disorders.
What this means for you:
If you pursue IV ketamine infusions for depression, clinics will almost always treat them as self-pay, and claims sent to your plan are very likely to be denied as non-covered, experimental treatment.
NOT STATED
Injection ketamine (IM / subcutaneous)
The same criteria document focuses on IV ketamine exclusions and does not create any separate rules for intramuscular ketamine in depression or chronic pain outside the anesthesia setting. When IV ketamine infusions are already excluded as not a covered benefit, clinics generally assume that off-label IM or subcutaneous protocols for depression will not be covered either.
What this means for you:
If a clinic offers IM or subcutaneous ketamine for depression, you should expect those sessions to be cash-pay and not reimbursed through your standard behavioral health or medical benefits.
NOT STATED
Oral / sublingual ketamine
The available Molina and state criteria documents do not mention oral or sublingual ketamine as treatment options for depression or related pain indications. Without any medical necessity criteria or benefit language for oral ketamine, there is no standard path for these formulations to be approved as covered services for depressive disorders.
What this means for you:
If you work with a clinic that prescribes oral or sublingual ketamine, you should assume you will be paying the clinic’s cash rate and not relying on your Molina coverage for the medication or associated visits.
Important fine print for Molina Healthcare members
- This summary is based on Molina and Iowa Medicaid materials, including the Spravato esketamine nasal spray clinical criteria document “Spravato esketamine nasal spray clinical criteria IME-PAM-021” and related coverage criteria posted by Iowa HHS at the state’s pharmacy and medical policy site.
- These documents describe how Spravato and ketamine-related services are evaluated but do not guarantee payment for any specific member, diagnosis, clinic, or claim.
- Your actual benefits depend on your individual contract and state program, so always review your Evidence of Coverage or Medicaid member handbook and call the Member Services number on your ID card before scheduling treatment.
- Molina operates plans in multiple states and program types, and Medicaid, marketplace, or other products may have different ketamine rules than those summarized here.
Does Point32Health (Harvard Pilgrim & Tufts Health Plan) Cover IV, Injection and Oral Ketamine?
No publicly available Point32Health policy has been found that clearly states whether IV, intramuscular, oral, or sublingual ketamine for depression is covered or excluded. The available Spravato medical necessity guideline focuses on intranasal esketamine and does not address other ketamine formulations or routes for depression.
*Based on available Point32Health policy materials including the Spravato medical necessity guideline.
NOT STATED
IV ketamine infusions
Point32Health (the parent company of Harvard Pilgrim and Tufts Health Plan) does not publish a clear medical policy on IV ketamine for depression. The available Spravato guideline addresses only intranasal esketamine and does not create coverage criteria for IV ketamine infusions.
What this means for you:
If you pursue IV ketamine for depression with a Point32Health plan, you should expect clinics to treat it as self-pay unless you can obtain clear written confirmation of coverage for your specific situation.
NOT STATED
Injection ketamine (IM / subcutaneous)
Available policy materials do not address intramuscular or subcutaneous ketamine for depression. Without published coverage criteria or medical necessity language for IM ketamine, clinics typically treat these protocols as non-covered services.
What this means for you:
If a clinic offers IM or subcutaneous ketamine for depression, you should plan on paying the clinic’s cash rate unless you receive explicit written confirmation that your plan will cover these sessions.
NOT STATED
Oral / sublingual ketamine
Point32Health’s available policy documents do not mention oral or sublingual ketamine for depression. Without any medical necessity criteria or coverage determination for these formulations, there is no clear path for oral ketamine to be treated as a covered benefit.
What this means for you:
If you work with a clinic that prescribes oral or sublingual ketamine, you should assume you will be paying out of pocket unless you obtain very specific written confirmation of coverage for your case.
Important fine print for Point32Health members
- This summary is based on available Point32Health policy materials including the Spravato medical necessity guideline.
- Point32Health operates Harvard Pilgrim Health Care and Tufts Health Plan, and publicly available policy materials may not reflect all internal coverage determinations for ketamine services.
- Your actual benefits depend on your individual contract, so always review your Evidence of Coverage and call the Member Services number on your ID card before scheduling treatment.
- Point32Health offers multiple products across different markets, and coverage rules may vary significantly between plan types and employer groups.
Does BlueCross BlueShield of Tennessee Cover IV, Injection and Oral Ketamine?
The medical policy on intravenous anesthetics lists intravenous ketamine for treatment-resistant depression and other psychiatric disorders as investigational and not covered. The policy focuses on IV administration and does not create explicit coverage criteria for intramuscular, oral, or sublingual ketamine for depression.
*Based on BlueCross BlueShield of Tennessee medical policy “Intravenous Anesthetics for the Treatment of Chronic Pain”.
NOT COVERED
IV ketamine infusions
The intravenous anesthetics policy specifically lists intravenous ketamine for treatment-resistant depression and other psychiatric disorders as investigational. When a service is classified as investigational in this way, it is not treated as a covered benefit for depressive disorders.
What this means for you:
If you pursue IV ketamine infusions for depression, clinics will almost always treat them as self-pay, and claims sent to your plan are very likely to be denied as investigational and not covered.
NOT STATED
Injection ketamine (IM / subcutaneous)
The medical policy manual does not include specific language addressing intramuscular or subcutaneous ketamine for depression. When IV ketamine is already classified as investigational and non-covered for psychiatric disorders, clinics generally assume that off-label IM or subcutaneous protocols will be treated the same way.
What this means for you:
If a clinic offers IM or subcutaneous ketamine for depression, you should expect those sessions to be cash-pay and not reimbursed as a standard mental health benefit.
NOT STATED
Oral / sublingual ketamine
The available medical policy materials do not mention oral or sublingual ketamine for depression. Without any supportive policy language or medical necessity criteria, there is no standard path for these formulations to be treated as covered benefits for depressive disorders.
What this means for you:
If you work with a clinic that prescribes oral or sublingual ketamine, you should assume you will be paying the clinic’s cash rate and not relying on your BlueCross BlueShield of Tennessee coverage for the medication or associated visits.
Important fine print for BlueCross BlueShield of Tennessee members
- This summary is based on BlueCross BlueShield of Tennessee materials including the medical policy “Intravenous Anesthetics for the Treatment of Chronic Pain” and related resources at Caremark pharmacy information and BCBST behavioral health provider resources.
- These materials describe how IV ketamine requests are evaluated but do not guarantee payment for any specific member, diagnosis, clinic, or claim.
- Your actual benefits depend on your individual contract, so always review your Evidence of Coverage and call the Member Services number on your ID card before scheduling treatment.
- BlueCross BlueShield of Tennessee offers multiple products, and employer plans or other arrangements may have different ketamine rules than those summarized here.
Frequently Asked Questions About Insurance Coverage of IV, Injection & Oral Ketamine
These answers are based on public policy documents from 18 major commercial insurers and focus on ketamine used to treat depression, not anesthesia or pain.
Do any insurance companies actually cover IV ketamine for depression?
Yes – but it’s rare and heavily restricted. In the table on this page, only 3 out of 18 major commercial insurers have a pathway on paper to cover IV ketamine for depression.
Even those require strict prior authorization and very specific criteria (usually treatment-resistant depression with multiple failed antidepressants and in-clinic monitoring). Coverage is never automatic and can vary by state, employer, and plan. For everyone else in the table, IV ketamine is treated as “experimental” or “not medically necessary,” which is insurer-speak for “we don’t cover this.”
If my plan says “NO” to IV ketamine, what are the chances it covers injection or oral ketamine instead?
Realistically, close to zero. When an insurer has gone on record saying no to IV ketamine for depression, that usually means it has decided ketamine as a depression treatment is experimental or not medically necessary.
IV is the most medicalized route (monitored, in-clinic, dosing protocols). If they won’t pay for that, they are not secretly covering intramuscular shots or compounded lozenges on the side.
In this table, “NO*” is there to flag that injection or oral ketamine is functionally a no, even if the policy doesn’t literally spell out the word “no” for that route.
My insurer is listed as “Not Stated.” Does that mean I might have a better chance of getting coverage?
Unfortunately, “Not Stated” usually behaves like “no coverage by default.” It only means there was no clear sentence in a public policy document that we could quote for that route.
It does not mean the insurer is on the fence or leaning toward yes. In practice, when a plan is silent about IV, injection, or oral ketamine for depression:
- There’s no defined benefit you can point to, and
- Clinics almost always treat that route as self-pay unless they get a very unusual one-off approval.
If your insurer is “Not Stated” for a route, the safe assumption is: “assume no unless you have a written yes for your specific plan.”
Why do insurers refuse IV, injection, and oral ketamine but still cover Spravato (esketamine nasal spray) more often?
Because they see them as two different worlds:
- IV, injection, and oral ketamine for depression are off-label uses of a generic anesthetic. Most insurers lump them into their “experimental / investigational” bucket and deny coverage.
- Spravato® (esketamine nasal spray) is an FDA-approved product for treatment-resistant depression, with a REMS program, specific dosing rules, and its own billing codes. That gives insurers a cleaner way to say, “We’ll cover this if you meet our criteria.”
So it’s common to see an insurer say no to IV / injection / oral ketamine while saying “yes, under strict rules” to Spravato in a separate policy.


